Hepatitis Prevention
Hepatitis Prevention - Related Videos
10:40
Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
0 Views •
Cited by 10 •
2012
An optical system was developed to visualize hepatic microcirculation with FITC-labeled erythrocytes and to measure the partial pressure of oxygen in the microvessels with laser-assisted phosphorimetry. This method can be used to investigate physiological and pathological mechanisms by analyzing microvascular structure, diameter, blood flow velocity, and oxygen tension.
09:35
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
0 Views •
Cited by 2 •
2017
Here we describe a newly developed hepatitis B virus (HBV) reporter system to monitor the early stages of the HBV life cycle. This simplified in vitro system will aid in the screening of anti-HBV agents using a high-throughput strategy.
06:00
Laparoscopic Anatomic S7+S8d Resection Preserving Inferior Right Hepatic Vein and S6 with Right Hepatic Vein Transection
0 Views •
2025
We present a laparoscopic technique for anatomic S7+S8d resection with right hepatic vein transection, preserving the inferior right hepatic vein and segment S6. Relying on meticulous anatomical landmarks without intraoperative ultrasound, this approach offers a precise and parenchyma-sparing option for dorsally located right-liver tumors, particularly in settings with limited advanced navigation resources.
11:29
Reusable Hepatic Imaging Tool: A Reusable 3D-Printed Tool for Hepatic Intravital Microscopy
0 Views •
2026
This protocol introduces a cutting-edge, Reusable Hepatic Imaging Tool (RHIT) for intravital microscopy (IVM) of live mice, which enhances tissue stability for rapid and acute experiments. The RHIT's 3D-printed design offers cost-effective production, scalability, and versatility, enabling prolonged observation of metabolic processes in mice of various sizes.
04:46
Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery
0 Views •
2025
The video demonstrates locoregional delivery of oncolytic viruses through hepatic arterial injection as a therapeutic approach for hepatocellular carcinoma. These viruses selectively replicate in tumor cells, inducing cell lysis and releasing tumor cell-associated antigens. This process triggers immunogenic cell death, inducing an anti-tumor response.
FAQs
Vaccination against hepatitis A and B protects through a different prevention target: it builds protective immunity before exposure, whereas hygiene, food and water safety, and safer sex reduce opportunities for exposure. Including vaccination in hepatitis prevention therefore addresses susceptibility directly, while behavioral and environmental measures reduce transmission pathways. Using both approaches broadens protection in clinical and public health programs.
Sterile injection equipment and screened blood products reduce opportunities for hepatitis transmission associated with exposure to potentially infected blood. These measures interrupt a specific route that hand hygiene, food safety, and safer sex do not address. Their use is especially relevant to clinical prevention programs because controlling blood exposure protects individuals and helps limit onward spread within healthcare and community settings.
Testing people with risk factors helps identify infected patients who might otherwise remain unrecognized. Once infection is identified, clinicians can provide appropriate treatment or counseling, supporting two goals: reducing the chance of onward transmission and limiting progression to chronic disease. Testing therefore connects individual clinical care with broader prevention efforts, rather than functioning only as a diagnostic activity.
A practical clinical approach combines assessment of relevant risk factors with vaccination when appropriate, testing, and counseling about exposure reduction. Identified patients can then receive appropriate treatment or further preventive guidance. This coordinated workflow links prevention, case identification, and disease management, allowing routine clinical care to contribute to reduced transmission, chronic disease, cirrhosis, liver cancer, and related deaths.
Integration is useful wherever people may face hepatitis exposure or where infected patients can be identified and supported. Routine clinical care can incorporate vaccination, risk-based testing, treatment, and counseling, while public health programs can reinforce these measures across populations. Combining both settings extends prevention beyond individual encounters and helps reduce transmission and long-term liver-related consequences.
Effective prevention can produce benefits at both transmission and disease levels. Reducing exposure opportunities and identifying infected patients helps limit onward spread, while vaccination and appropriate treatment or counseling support protection and disease control. Over time, these combined measures can lower chronic disease and its serious consequences, including cirrhosis, liver cancer, and hepatitis-related deaths.